Morgan Stanley's Schedule 13G Filing for Evoke Pharma Inc

Morgan Stanley and Morgan Stanley Smith Barney LLC have filed a Schedule 13G with the SEC, disclosing their beneficial ownership of 10.5% of the common stock of Evoke Pharma Inc. The filing indicates that the shares are held in the ordinary course of business and not for the purpose of influencing the control of the issuer. The filing is made under Rule 13d-1(b) and includes a joint filing agreement and item 7 information as exhibits. The filing is signed by authorized signatories from both entities, Christopher O'Hara for Morgan Stanley and David Galasso for Morgan Stanley Smith Barney LLC.